What the Landmark ORBITA Trial Means for Patients, Cardiologists and the Future of Heart Disease Management
A Landmark Study That Sent Shockwaves Through Cardiology
On 2 November 2017, The Lancet, one of the world's most prestigious medical journals,
published a landmark clinical trial that has challenged one of the most deeply held beliefs in
modern cardiology. The study, known as ORBITA (Objective Randomised Blinded
Investigation with Optimal Medical Therapy of Angioplasty in Stable Angina), has
generated intense debate among cardiologists across the world and may ultimately reshape
the management of patients with stable coronary artery disease.
For nearly four decades, angioplasty has been considered the preferred treatment for
relieving chest pain in patients with stable angina. Although previous clinical trials had
already demonstrated that angioplasty does not reduce the risk of future heart attacks or
improve survival in stable patients, many physicians continued to recommend the
procedure because it was believed to provide superior relief of angina and improve quality of
life.
The ORBITA trial has now questioned even that long-standing assumption.
Understanding Stable Angina
To appreciate the significance of ORBITA, it is important to understand what is meant by
stable angina.
Stable angina refers to chest discomfort that occurs predictably when the heart is made to
work harder, such as during:
● Walking
● Climbing stairs
● Emotional stress
● Physical exertion
Typically, the pain:
● lasts only a few minutes,
● disappears with rest,
● or is relieved promptly by nitrate medications such as nitroglycerin.
These patients are different from those experiencing an acute heart attack or unstable
angina. Their symptoms are predictable and generally occur because narrowed coronary
arteries are unable to supply sufficient blood during increased demand.
For decades, many such patients have been advised to undergo Percutaneous Coronary
Intervention (PCI)—commonly known as angioplasty with stent implantation—to relieve
symptoms.
What Makes ORBITA So Extraordinary?
The ORBITA trial is unique because it is the first placebo-controlled trial ever conducted
for angioplasty since the procedure was first introduced in 1977.
Drug therapies are routinely tested against placebos before becoming accepted medical
practice. Surprisingly, despite millions of angioplasty procedures being performed worldwide
over four decades, no one had previously asked a simple but fundamental question:
How much of the improvement after angioplasty is actually due to the
procedure itself, and how much is due to the placebo effect?
ORBITA was specifically designed to answer that question.
How the Trial Was Conducted
The ORBITA investigators enrolled 200 patients with stable single-vessel coronary artery
disease.
Before any procedure was performed, every patient underwent six weeks of intensive
optimisation of medical therapy. Their anti-anginal medications were carefully adjusted to
achieve the best possible symptom control.
Only after this optimisation were patients randomly assigned to one of two groups.
Group One
Patients underwent genuine angioplasty:
● The narrowed artery was opened.
● A coronary stent was implanted.
● Blood flow was restored in the treated artery.
Group Two
Patients underwent a sham (placebo) procedure.
Everything appeared identical to the real intervention.
Patients were taken into the catheterisation laboratory, sedated, and underwent coronary
angiography. However, the blocked artery was not opened and no stent was implanted.
Importantly:
● Patients did not know which procedure they had received.
● The physicians assessing their symptoms afterwards also remained blinded.
This rigorous double-blind, placebo-controlled design is regarded as the highest standard of
scientific research because it removes patient expectations and physician bias from
influencing the results.
The Surprising Results
After six weeks of follow-up, investigators compared the two groups.
Contrary to decades of conventional belief, the study found that patients who underwent
angioplasty did not experience a statistically significant improvement in:
● Exercise time
● Walking capacity
● Frequency of chest pain
● Overall quality of life
when compared with patients who underwent the sham procedure.
Although angioplasty successfully opened the narrowed coronary arteries and significantly
improved blood flow as measured by physiological testing, these improvements did not
translate into meaningful clinical benefits over placeboduring the study period.
This finding surprised cardiologists around the world because it challenged the principal
justification for performing elective angioplasty in patients with stable angina.
If angioplasty neither prolongs life nor prevents heart attacks—and now may not significantly
outperform a placebo in relieving symptoms—then an important question naturally arises:
Should every patient with stable angina continue to undergo angioplasty?
ORBITA Did Not Appear Overnight
The ORBITA findings did not emerge in isolation.
Earlier landmark clinical trials had already raised important questions regarding the routine
use of angioplasty in stable coronary artery disease.
Among the most influential were:
● COURAGE Trial
● BARI 2D Trial
Both studies consistently demonstrated that, in patients with stable coronary artery
disease, angioplasty offered no advantage over optimal medical therapy in reducing:
● death,
● future heart attacks,
● or long-term survival.
These findings had already become widely accepted within academic cardiology.
However, one important argument remained in favour of angioplasty.
While it did not improve survival, cardiologists believed it offered superior relief of angina
and therefore improved quality of life.
This belief became the principal reason for recommending elective angioplasty in stable
patients.
With the publication of ORBITA, even this long-standing assumption has now been
challenged.
Non-invasive therapies may also play an important role for selected patients. At Heal
YourHeart, Enhanced External Counterpulsation (EECP) is offered as a treatment option for
patients with chronic stable angina who remain symptomatic despite optimal medical therapy
or are not suitable candidates for revascularization. By promoting coronary collateral
circulation and reducing cardiac workload, EECP complements guideline-directed medical
management in appropriately selected patients.
For More Details About EECP Call : 9003070065 / 9003070064
• ORBITA Trial (BMJ): https://www.bmj.com/content/359/bmj.j5076 • Related article: https://share.google/joJzFwvfA7yvwba74
Dr. S. Ramasamy, MBBS, PhD (Cardio), FRCP,FACC.
EECP Consultant
Director, Heal Your Heart EECP Centres
In Charge, Vaso-Meditech EECP Public-Private Partnership Programme, Tamil Nadu
Government Medical Colleges
Comments
Post a Comment